Division
HEAL Study
Title
Identifying Regional “Hotspots” and Potential Correlates of Precipitated Withdrawal During Buprenorphine Induction in Fentanyl Users Through Prescriber Survey Responses and Patient Urine Drug Test Results (Buprenorphine-Precipitated Withdrawal Hotspots and Correlates)
Short Description
This study will characterize the regional variability in the prevalence of prescriber-reported precipitated withdrawal during BUP induction for individuals using fentanyl and other non-prescribed and/or illicit drugs in approximately 279 counties in the United States.
Release Date
Jun 03, 2025
Description
This study is a one group, cross-sectional survey study. Active buprenorphine (BUP) prescribers will be recruited to participate in an online survey of clinical program features, characteristics of patients with opioid use disorder (OUD), patients’ experience with precipitated withdrawal during BUP induction, and patients’ fentanyl use at a single time point. Millennium Health (MH) will provide urine drug test (UDT) results from the counties of prescribers who participated in the survey. Both the survey and UDT results will be obtained from addiction treatment clinics. The UDT results and survey data will be merged at the county level to assess the association between precipitated withdrawal issues and fentanyl, fentanyl analogues, and other drugs of abuse.
Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Data
Study Links
Study Documents
Division
HEAL Study
Investigator(s)
Title
Integrating Pharmacy-Based Prevention and Treatment of Opioid and Other Substance Use Disorders: A Survey of Pharmacists and Stakeholders
Short Description
The overall goal of this study is to investigate community pharmacists’ knowledge of, attitudes about, and intention to provide patient care and services for Screening for substance use/misuse and Referral to Treatment (SRT) for substance use disorders (SUDs) and Medication treatment for Opioid Use Disorders (MOUD).
Release Date
May 23, 2025
Description
Study aims are to: Aim 1: Conduct a survey of licensed community pharmacists to study their knowledge of, attitudes about, and intention to provide patient care and services for SRT and MOUD; and Aim 2: Conduct a qualitative interview of a sample of up to 50 survey participants (range: 20 to 50 participants) from Aim 1 to further assess survey participants’ interest in implementing preventive care services for SUDs and medication therapy management for patients with opioid use disorder (OUD) in their practice. Together, the results will inform pharmacy-based study designs and future directions for the NIDA National Drug Abuse Treatment Clinical Trials Network (CTN) studies as well as training and educational needs for community pharmacists.
Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Data
Study Links
Study Documents

Opioid Overdose Knowledge Scale

Submitted by cbethel on
Abbreviation
OOKS
Description
The Opioid Overdose Knowledge Scale (OOKS) is a psychometric instrument used to assess an individual's knowledge about opioid overdose risks, signs, actions to take during an overdose, and the correct use of naloxone. It's often used to evaluate the effectiveness of opioid overdose education and naloxone distribution programs.
Category
Substance Use
Clinic Related Surveys
Impulsivity and General Trait & Behavior Scales
Subcategory
Diagnostic
Division
HEAL Study
Title
Suicide Prediction and Prevention for People at Risk for Opioid Use Disorder
Short Description
This study integrates the Mental Health Research Network (MHRN) suicide risk models into Opioid Wizard, an electronic health record (EHR) clinical decision support (CDS) to identify and treat patients at high risk of opioid use disorder (OUD)/overdose or diagnosed with OUD, to alert primary care clinicians (PCCs) to patients at elevated risk for suicide and guide them through structured suicide risk assessment.
Release Date
Apr 22, 2025
Description
When a patient is at elevated risk of suicide, the PCC will be prompted by Opioid Wizard to complete the Columbia-Suicide Severity Risk Scale (CSSRS), easily available to all PCCs in the EHR and saved as discrete data elements. Risk-based (depending on CSSRS score) referral and follow-up recommendations for suicide prevention will be given, with specific care recommendations ranging from care as usual (very low risk) to referral to behavioral health for evaluation and safety planning (moderate to high risk) to immediate evaluation in the emergency department and potential inpatient admission (very high risk), building on workflows developed for use by care managers in in our recently completed suicide prevention trial of over 19,000 people at elevated risk of suicide.
Keywords
Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Data
Study Links
Study Documents